Understanding the Tumor Microenvironment and Radioresistance by Combining Functional Imaging With Global Gene Expression

Seminars in Radiation Oncology

Volumn 23, Issue 4, 2013, Pages 296-305

  Dewhirst, Mark W ^a   Chi, Jen Tsan ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHROMOGRANIN A; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; IMATINIB; INOSITOL TRISPHOSPHATE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROGESTERONE RECEPTOR; PYRUVATE DEHYDROGENASE KINASE 2; SIALYLTRANSFERASE; VASCULAR CELL ADHESION MOLECULE 1;

ANAEROBIC METABOLISM; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER SURVIVAL; CELL ADHESION; CELL PROLIFERATION; CHEMORADIOTHERAPY; CONTRAST ENHANCEMENT; DNA DAMAGE; DNA REPAIR; EXTERNAL BEAM RADIOTHERAPY; EXTRACELLULAR MATRIX; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GLIOBLASTOMA; GLUCOSE METABOLISM; HEAD AND NECK CANCER; HUMAN; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN DEGRADATION; RADIOSENSITIVITY; RECURRENCE FREE SURVIVAL; SOFT TISSUE SARCOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER;

ANIMALS; DIAGNOSTIC IMAGING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PHENOTYPE; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84883548331     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2013.05.004     Document Type: Article

References (46)

1. Torres-Roca J.F., Stevens C.W. Predicting response to clinical radiotherapy: Past, present, and future directions. Cancer Control 2008, 15(2):151-156.
2. Lambin P., van Stiphout R., Starmans M.H.W., et al. Predicting outcomes in radiation oncology-multifactorial decision support systems. Nat Rev Clin Oncol 2013, 10(1):27-40.
3. Begg A.C. Predicting recurrence after radiotherapy in head and neck cancer. Semin Radiat Oncol 2012, 22(2):108-118.
4. Begg A.C. Predicting response to radiotherapy: Evolutions and revolutions. Int J Radiat Biol 2009, 85(10):825-836.
5. Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-A systematic review and meta-analysis. Radiother Oncol 2011, 100(1):22-32.
6. Harada H. How can we overcome tumor hypoxia in radiation therapy?. J Radiat Res 2011, 52(5):545-556.
7. Le Q.T., Harris J., Magliocco A.M., et al. Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation therapy oncology group trial 90-03. J Clin Oncol 2009, 27(26):4281-4286.
8. Ross J.S., Hatzis C., Symmans W.F., et al. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 2008, 13(5):477-493.
9. Chen J.L.Y., Lucas J.E., Schroeder T., et al. The genomic analysis of lactic acidosis and acidosis response in human cancers. PLoS Genet 2008, 4(12).
10. Chi J.T., Wang Z., Nuyten D.S.A., et al. Gene expression programs in response to hypoxia: Cell type specificity and prognostic significance in human cancers. PLoS Med 2006, 3(3):395-409.
11. Winter S.C., Buffa F.M., Silva P., et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 2007, 67(7):3441-3449.
12. Pramana J., Van den Brekel M.W.M., Van Velthuysen M.L.F., et al. Gene expression profiling to predict outcome after chemoradiation in head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 69(5):1544-1552.
13. Chang H.Y., Sneddon J.B., Alizadeh A.A., et al. Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds. PLoS Biol 2004, 2(2):206-214.
14. Gatza M.L., Kung H.N., Blackwell K.L., et al. Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Res 2011, 13(3).
15. Eschrich S.A., Pramana J., Zhang H.L., et al. A gene expression model of intrinsic tumor radiosensitivity: Prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys 2009, 75(2):489-496.
16. Eschrich S.A., Fulp W.J., Pawitan Y., et al. Validation of a radiosensitivity molecular signature in breast cancer. Clin Cancer Res 2012, 18(18):5134-5143.
17. Weichselbaum R.R., Ishwaran H., Yoon T., et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A 2008, 105(47):18490-18495.
18. Singh D., Febbo P.G., Ross K., et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002, 1(2):203-209.
19. Lyng H., Svendsrud D.H., Brovig R.S., et al. Molecular markers for lymph node involvement in advanced cervical carcinomas. Radiother Oncol 2006, 78:S60-S61.
20. Lando M., Holden M., Bergersen L.C., et al. Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer. PLoS Genet 2009, 5(11).
21. Shedden K., Taylor J.M.G., Enkemann S.A., et al. Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nat Med 2008, 14(8):822-827.
22. Zahra M.A., Hollingsworth K.G., Sala E., et al. Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol 2007, 8(1):63-74.
23. Heijmen L., Verstappen M., ter Voert E., et al. Tumour response prediction by diffusion-weighted MR imaging: Ready for clinical use?. Crit Rev Oncol Hematol 2012, 83(2):194-207.
24. Bollineni V.R., Wiegman E.M., Pruim J., et al. Hypoxia imaging using positron emission tomography in non-small cell lung cancer: Implications for radiotherapy. Cancer Treat Rev 2012, 38(8):1027-1032.
25. Osborne J.R., Port E., Gonen M., et al. F-18-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: Microarray and immunohistochemical analysis. J Nucl Med 2010, 51(4):543-550.
26. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
27. Nair V.S., Gevaert O., Davidzon G., et al. Prognostic PET F-18-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer. Cancer Res 2012, 72(15):3725-3734.
28. Lee J.D., Yun M.J., Lee J.M., et al. Analysis of gene expression profiles of hepatocellular carcinomas with regard to F-18-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging 2004, 31(12):1621-1630.
29. Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, et al: Correlation of dynamic PET and gene array data in patients with gastrointestinal stromal tumors. Sci World J 2012. http://dx.doi.org/10.1100/2012/721313.
30. Yamamoto S., Maki D.D., Korn R.L., et al. Radiogenomic analysis of breast cancer using MRI: A preliminary study to define the landscape. Am J Roentgenol 2012, 199(3):654-663.
31. Halle C., Andersen E., Lando M., et al. Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI. Cancer Res 2012, 72(20):5285-5295.
32. Tofts P.S. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997, 7(1):91-101.
33. Moon E.J., Brizel D.M., Chi J.-T.A., et al. The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid Redox Signal 2007, 9(8):1237-1294.
34. Hockel M., Schlenger K., Aral B., et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996, 56(19):4509-4515.
35. Vaupel P., Kelleher D.K., Hockel M. Oxygenation status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001, 28(2):29-35.
36. Fyles A.W., Milosevic M., Wong R., et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998, 48(2):149-156.
37. Chi J.T., Thrall D.E., Jiang C., et al. Comparison of genomics and functional imaging from canine sarcomas treated with thermoradiotherapy predicts therapeutic response and identifies combination therapeutics. Clin Cancer Res 2011, 17(8):2549-2560.
38. Yan H., Parsons D.W., Jin G., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360(8):765-773.
39. Dang L., White D.W., Gross S., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462(7274):739-744.
40. Choi C., Ganji S.K., DeBerardinis R.J., et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012, 18(4):624-629.
41. Gerlinger M., Rowan A.J., Horswell S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366(10):883-892.
42. Kreso A., O'Brien C.A., van Galen P., et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013, 339(6119):543-548.
43. Bamezai A. Mouse Ly-6 proteins and their extended family: Markers of cell differentiation and regulators of cell signaling. Arch Immunol Ther Exp 2004, 52(4):255-266.
44. Hong S.W., Jin D.H., Shin J.S., et al. Ring finger protein 149 is an E3 ubiquitin ligase active on wild-type v-Raf murine sarcoma viral oncogene homolog B1 (BRAF). J Biol Chem 2012, 287(28):24017-24025.
45. Harvey C.B., Wang Y.X., Darmoul D., et al. Characterisation of a human homologue of a yeast cell division cycle gene, MCM6, located adjacent to the 5'' end of the lactase gene on chromosome 2q21. FEBS Lett 1996, 398(2-3):135-140.
46. Kelly T., Huang Y., Simms A.E., et al. Fibroblast activation protein-alpha: A key modulator of the microenvironment in multiple pathologies. Int Rev Cell Mol Biol 2012, 297:83-116.